PMAM
MIRM icon

Picton Mahoney Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Picton Mahoney Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.58M Sell
47,679
-26,439
-36% -$2.65M 0.04% 335
2026
Q1 		$6.85M Buy
74,118
+72,698
+5,120% +$6.84M 0.05% 314
2025
Q4 		$112K Buy
+1,420
New +$102K ﹤0.01% 857

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Picton Mahoney Asset Management's MIRM Position: Q2 2026 in Review

Picton Mahoney Asset Management reduced its Mirum Pharmaceuticals (MIRM) stake by 36% in Q2 2026, selling an estimated $2.65M and leaving 47,679 shares worth $5.58M. The position accounts for 0.04% of the portfolio, ranked #335.

Picton Mahoney Asset Management first reported a position in MIRM in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.85M in Q1 2026. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Picton Mahoney Asset Management held 47,679 shares of Mirum Pharmaceuticals worth $5.58M as of Q2 2026.
  • Picton Mahoney Asset Management sold 26,439 Mirum Pharmaceuticals shares in Q2 2026, an estimated $2.65M.
  • Mirum Pharmaceuticals made up 0.04% of Picton Mahoney Asset Management's portfolio in Q2 2026, its #335 holding.
  • Picton Mahoney Asset Management first reported a position in Mirum Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Picton Mahoney Asset Management's Mirum Pharmaceuticals position peaked at $6.85M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.